SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amidst discussions around meme coins and potential market manipulation, with some community members expressing frustration over its recent performance. There are those who believe in its potential and encourage holding, while others are pointing to concerns about its circulating supply and the lack of utility. Conversations also mention other meme coins like DOGE and BONK, reflecting the speculative nature of the asset.

Bounce Token

Bounce Token is experiencing heightened interest as the community anticipates a potential breakout, drawing comparisons to previous rallies. Discussions revolve around promising utility, growing bid sizes, and possible integration with AI, with some community members pointing to bullish technical indicators. Despite some skepticism, there's optimism for a significant run, with attention focused on key price levels.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE is trending as the community rallies around the OG meme coin, anticipating potential listings and partnerships. Discussions are centered on community building and expressing bullish sentiment, emphasizing the coin's potential within the meme culture landscape. The community is actively participating in raids and spaces, further amplifying the coin's visibility.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending amid discussions about potential ETFs and its growing meme coin economy, with community members highlighting the performance of Solana-based tokens. The community is closely watching the $SOL chart, debating potential short-term buying opportunities and future price movements. Several Solana ecosystem coins such as $CAW (Crow with Knife), $UPDOG, and $FIRECOIN are also gaining traction.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is trending as the community discusses its potential, quantum-resistant technology, and real-world asset tokenization. Bullish sentiment is fueled by anticipation of alt season and speculation around partnerships, while some express frustration with the current price action and the Algorand Foundation. Chatter also includes commentary about specific users and their past predictions.

Pojak watched as the world played hot potato with CTO shit coins. Now, it's his moment. With Pepe's legendary meme power and Wojak's emotional depth, Pojak brings a new level of influence, wealth, and ethics. Born into meme royalty with luxury and wisdom from Pepe and Wojak, he faced hardship when the original developer rugged the project. The community rose up and took control. Pojak was reborn, stronger and more determined.

Pojak

Pojak ($PJ) is trending, with many noting its association with Phantom Wallet and the Solana ecosystem. The community is highlighting bullish sentiment, with many suggesting it's poised for a breakout. However, some users are advising caution, drawing comparisons to other hyped coins.

Memecoin on Cronos launched by the Cro Crow community

crow with knife

Crow with Knife ($CAW) is gaining attention as a multichain meme coin, with its community emphasizing its deflationary mechanism and organic growth. Discussions highlight its presence on multiple chains like Solana, CRO, and Base, with some suggesting staking opportunities may be coming. The community is actively using "caw caw caw" to express their excitement.

A composable native asset bridge with unified liquidity and instant guaranteed finality

Stargate

Stargate is trending as community members discuss its role in bridging and burning $CAW tokens across multiple blockchains. Some users highlight a recent acquisition deal with $ZRO, while others are drawn to Stargate's integration with Hyperliquid for one-click deposits. The community is actively bridging, burning, and following the crow with knife.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd.

SU Group (SUGP) is trending due to its low float and a recently announced, record-breaking contract, leading to speculation about a potential short squeeze. Traders are drawing comparisons to other Hong Kong-based stocks that have experienced significant gains. The community is actively monitoring the stock, also noting its regained NASDAQ compliance and high cost to borrow.

MLN is the official token of Enzyme. Founded in 2017, Enzyme is the global infrastructure for tokenized finance. Enzyme provides industry leaders with a comprehensive suites of Vault-As-A-Service and Financial Instruments products to manage on-chain assets efficiently, optimize operational processes, and develop innovative financial strategies tailored to their unique goals and challenges.

Melon

Recent price action in Melon is capturing the attention of traders, with community members actively discussing potential breakouts and comparing it to other low-supply coins. Speculation is fueled by its limited token supply and historical price movements, with some anticipating a significant rally. Others urge caution, citing concerns about potential pump-and-dump schemes.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BMY Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?

Bristol Myers stock slips below its 50-day average as generic pressure, high debt, and trimmed earnings outlook weigh on sentiment

Could MRNA's Upcoming Product Launches Reduce COVID Sales Dependency?

Moderna plans up to 10 product launches over four years, aiming to cut reliance on fading COVID-19 vaccine sales.

BMY Reports Positive Data From a Late-Stage Multiple Myeloma Study

Bristol Myers reports positive phase III results for iberdomide in multiple myeloma, advancing its CELMoD pipeline and portfolio expansion.

MRNA Stock Rises as Updated COVID-19 Jab Shows Strong Immune Response

Moderna jumps after its updated formulation of Spikevax shows an over 8-fold increase in neutralizing antibodies against the LP.8.1 COVID-19 variant in phase IV study.

COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths

MRNA, BNTX, PFE and NVAX stocks fall as health officials reportedly plan to link COVID-19 vaccines to child deaths ahead of a key CDC meeting.

BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?

Bristol Myers and BioNTech report strong mid-stage lung cancer trial data for pumitamig, showing high response rates and manageable safety.

Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold? 

Bristol Myers struggles with falling shares and legacy drug headwinds, but growth drugs and new approvals help steady revenues.

SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study

Summit Therapeutics plunges 25% after its HARMONi study shows sharp regional differences in lung cancer trial outcomes.

Pfizer Inc. (PFE) and BioNTech SE (BNTX) announced on Monday that their updated COVID-19 vaccine elicited a robust immune response in a late-stage trial among adults aged 65 and older, as well as those aged 18 through 64 with at least one underlying risk condition.The trial was aimed at evaluating the safety, tolerability, and immunogenicity of a 30-µg dose of the updated vaccine. Preliminary data showed a robust increase in neutralizing antibodies targeting the LP.8.1 sublineage of the COVID-19-causing virus following vaccination, the companies <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-announce-topline-data-demonstrating">said</a>.It added that after 14 days of vaccination, LP.8.1-neutralizing antibody titers exceeded pre-vaccination levels, on average, by at least 4-fold in both age groups. The study enrolled 100 participants.While <a href="https://stocktwits.com/symbol/PFE">PFE stock</a> traded 2% lower at the time of writing, <a href="https://stocktwits.com/symbol/BNTX">BNTX stock</a> fell 7%. On Stocktwits, retail sentiment around PFE stock stayed within ‘bearish’ territory over the past 24 hours, while message volume stayed at ‘low’ levels.<figure class="image"><img style="aspect-ratio:573/59;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_08_at_9_33_39_AM_png_3e721fcb96.webp" alt="PFE's Sentiment Meter and Message Volume as of 9:33 a.m. ET on Sept. 8, 2025 | Source: Stocktwits" width="573" height="59"><figcaption>PFE's Sentiment Meter and Message Volume as of 9:33 a.m. ET on Sept. 8, 2025 | Source: Stocktwits</figcaption></figure>Meanwhile, sentiment around BNTX stayed at ‘extremely bullish’ levels, while retail chatter remained ‘high’.<figure class="image"><img style="aspect-ratio:576/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_08_at_9_34_58_AM_png_9bf1a11796.webp" alt="BNTX's Sentiment Meter and Message Volume as of 9:35 a.m. ET on Sept. 8, 2025 | Source: Stocktwits" width="576" height="62"><figcaption>BNTX's Sentiment Meter and Message Volume as of 9:35 a.m. ET on Sept. 8, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed surprise at PFE stock trading lower after the news.<stembedurl>https://stocktwits.com/Wallst45/message/627799089</stembedurl>The companies stated that the data is intended to reinforce previous findings from vaccine studies and is not meant to replace the post-marketing commitments requested by the U.S. Food and Drug Administration. The safety profile of the vaccine was consistent with previous studies in the trial, with no new safety concerns identified, they added.The updated vaccine received FDA approval last month. To date, five billion doses of the Pfizer-BioNTech COVID-19 vaccine have been distributed globally.While PFE stock is down about 8% this year, BNTX stock is down over 8%.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/rapport-stock-soars-pre-market-to-head-toward-all-time-highs/chwWU5HRdrd">Rapport Therapeutics Stock Rockets 204% Pre-Market To Head Toward All-Time Highs – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, Ruth Jones, Immunization Nurse, holds a Pfizer-BioNTech COVID-19 vaccine (brand name: Comirnaty) at Borinquen Health Care Center on May 29, 2025 in Miami, Florida

Pfizer, BioNTech’s Updated COVID-19 Vaccine Shows Robust Immune Response In Late-Stage Study – More Details Inside

The companies stated that the data is intended to reinforce previous findings from vaccine studies and is not meant to replace the post-marketing commitments requested by the U.S. Food and Drug Administration. 

Equity

The companies stated that the data is intended to reinforce previous findings from vaccine studies and is not meant to replace the post-marketing commitments requested by the U.S. Food and Drug Administration. 


BioNTech SE (BNTX) announced on Friday that a late-stage trial, conducted by its partner Duality Biologics in China, has met its primary endpoint of progression-free survival at a pre-specified interim analysis. The trial is evaluating Trastuzumab Pamirtecan versus Trastuzumab Emtansine in patients with certain types of breast cancer.Shares of the company traded 10% higher in the pre-market session on Friday. The <a target="_blank" rel="noopener noreferrer nofollow" href="https://investors.biontech.de/news-releases/news-release-details/biontech-and-dualitybio-announce-phase-3-trial-adc-candidate">trial</a> enrolled 228 patients with HER2-positive unresectable or metastatic breast cancer, an aggressive form of the disease that has spread and cannot be surgically removed, who previously received Trastuzumab and a taxane-based chemotherapy.On Stocktwits, retail sentiment around BNTX stock jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:577/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_05_at_8_57_36_AM_png_5a9988a80e.webp" alt="BNTX's Sentiment Meter and Message Volume as of 8:57 a.m. ET on Sept. 5, 2025 | Source: Stocktwits" width="577" height="60"><figcaption>BNTX's Sentiment Meter and Message Volume as of 8:57 a.m. ET on Sept. 5, 2025 | Source: Stocktwits</figcaption></figure> DualityBio now plans to discuss the next steps with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China regarding the submission of an application for Trastuzumab Pamirtecan approval.DualityBio Global Medical Officer Hua Mu noted that breast cancer has a high incidence rate in China, with over 350,000 new cases annually.“Together with our partner BioNTech, we plan the development of Trastuzumab Pamirtecan in further tumor types towards BLA application in other regions including the United States and the European Union to maximize its potential for patients around the world,” Mu said.BioNTech also noted that this is the first positive late-stage data readout achieved in the collaboration between the two companies initiated in April 2023. The collaboration aims to accelerate the development of differentiated antibody drug-conjugate therapeutics for solid tumors.BioNTech holds global commercial rights for Trastuzumab Pamirtecan, while DualityBio has commercial rights for Mainland China, Hong Kong Special Administrative Region, and Macau Special Administrative Region.BNTX stock is down by 9% this year but up by about 15% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/tesla-proposes-whopping-1-trillion-pay-package-for-ceo-elon-musk/chwIJkaRdpr">Tesla Proposes Whopping $1 Trillion Pay Package For CEO Elon Musk</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the BioNTech logo is displayed on a smartphone screen. (Photo illustration by Cheng Xin/Getty Images)

Why Did BioNTech Stock Surge 10% Pre-Market Today?

DualityBio now plans to discuss the next steps with the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) of China regarding the submission of an application for Trastuzumab Pamirtecan approval.

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

BioNTech SE - ADR

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Netflix Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$105.14
Prev Close	$105.08
Open	$103.10
Dividend Yield	0.00%
50-Day Moving Average	$103.99
Beta	0.79
Avg. Volume	1.23M
PE Ratio	-66.39

52-Week High	$129.27
52-Week Low	$81.20
Market Capitalization	$25.28B
EPS (Annual)	-$2.99
Price to Book	1.16
Revenue Per Employee	$439,432.88
Enterprise Value/EBITDA	N/A

BNTX
BioNTech SE - ADR

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BNTX News

BNTXBioNTech SE - ADR